AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market Read More »
